Literature DB >> 11455478

Microcirculatory derangements in acute pancreatitis.

M D Menger1, T Plusczyk, B Vollmar.   

Abstract

During the past decade, a considerable number of experimental studies have confirmed the hypothesis that microcirculatory derangements play a pivotal role in the pathogenesis of acute pancreatitis, including the process of conversion from edematous to necrotizing injury. Predominant microcirculatory disorders are nutritive capillary perfusion failure, with the consequence of prolonged focal hypoxia or anoxia, and inflammation-associated microvascular leukocyte recruitment, CD11b- and intercellular adhesion molecule (ICAM)-1-mediated leukocyte-endothelial cell interaction and loss of endothelial integrity, which may result in both edema formation and necrosis. A variety of proinflammatory mediators, such as oxygen radicals, leukotrienes, platelet-activating factor, and interleukins, but also bradykinin and endothelins, seem to be involved in triggering the manifestations of these microcirculatory disorders. In contrast, the anti-inflammatory interleukin-10, as well as nitric oxide, are thought to be capable of protecting from these pancreatitis-associated microvascular injuries. This knowledge may be encouraging for the development of novel therapeutic strategies, aiming at the attenuation of microcirculatory disorders, and, thus, preventing tissue injury in acute pancreatitis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11455478     DOI: 10.1007/s005340170015

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Surg        ISSN: 0944-1166


  22 in total

1.  Immunomodulation in surgical practice.

Authors:  R Andersson; B Andersson; E Andersson; G Eckerwall; M Nordén; B Tingstedt
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

2.  Acute pancreatitis--from cellular signalling to complicated clinical course.

Authors:  Roland Andersson; Bodil Andersson; Ellen Andersson; Jakob Axelsson; Gunilla Eckerwall; Bobby Tingstedt
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

3.  Pioglitazone, a specific ligand of peroxisome proliferator-activated receptor-gamma, protects pancreas against acute cerulein-induced pancreatitis.

Authors:  Peter C Konturek; Artur Dembinski; Zygmunt Warzecha; Grzegorz Burnat; Piotr Ceranowicz; Eckhart G Hahn; Marcin Dembinski; Romana Tomaszewska; Stanislaw J Konturek
Journal:  World J Gastroenterol       Date:  2005-10-28       Impact factor: 5.742

4.  Embryonic natural orifice transluminal endoscopic surgery in the treatment of severe acute pancreatitis complicated by abdominal compartment syndrome.

Authors:  Hui-Ming Zhu; Shao-Qing Guo; Xiu-Min Liao; Li Zhang; Li Cai
Journal:  World J Emerg Med       Date:  2015

5.  The protective effects of rutaecarpine on acute pancreatitis.

Authors:  Lu Yan; Qing-Fu Li; Yan-Ting Rong; Yong-Heng Chen; Zhao-Hong Huang; Zhi-Zhi Wang; Jie Peng
Journal:  Oncol Lett       Date:  2017-12-20       Impact factor: 2.967

Review 6.  Sensory nerves and pancreatitis.

Authors:  Qingfu Li; Jie Peng
Journal:  Gland Surg       Date:  2014-11

Review 7.  Severe acute pancreatitis: pathogenetic aspects and prognostic factors.

Authors:  Ibrahim-A Al Mofleh
Journal:  World J Gastroenterol       Date:  2008-02-07       Impact factor: 5.742

8.  Changes of cytosolic [Ca2+]i in neutrophils in pancreatic microcirculation of rats with caerulein-induced acute pancreatitis under fluid shear stress.

Authors:  Zong-Guang Zhou; You-Qin Chen; Xu-Bao Liu; Wei-Ming Hu; Bo-Le Tian; Huai-Qing Chen
Journal:  World J Gastroenterol       Date:  2004-11-01       Impact factor: 5.742

9.  Role of COX-2 in microcirculatory disturbance in experimental pancreatitis.

Authors:  Wen-Wei Yan; Zong-Guang Zhou; You-Dai Chen; Hong-Kai Gao
Journal:  World J Gastroenterol       Date:  2004-07-15       Impact factor: 5.742

10.  Ischemic preconditioning attenuates capillary no-reflow and leukocyte adherence in postischemic pancreatitis.

Authors:  R Obermaier; E von Dobschuetz; O Drognitz; U T Hopt; S Benz
Journal:  Langenbecks Arch Surg       Date:  2004-01-09       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.